Rallybio (RLYB) Stock Price, News & Analysis

Company Overview

Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets.

Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy. The program is designed to target the HPA-1a antigen and potentially reduce the risk of severe bleeding and related complications in newborns.

The company has also advanced programs involving complement biology, including RLYB116, an investigational complement inhibitor intended for potential use in diseases driven by inappropriate complement activation. Rallybio’s research and development strategy is centered on identifying significant unmet medical needs and advancing targeted therapies through clinical development and potential regulatory approval.

Key Stats

• Today's Range: $15.50 to $16.46
• 50-Day Range: $15.93 to $17.22
• 52-Week Range: $3.67 to $17.57
• Volume: 52,619 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Rallybio Stock Analysis - MarketRank™

Rallybio scored higher than 23% of companies evaluated by MarketBeat, and ranked 765th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Rallybio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Rallybio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Rallybio is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rallybio is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.86% of the float of Rallybio has been sold short.

Short Interest Ratio / Days to Cover

Rallybio has a short interest ratio ("days to cover") of 7.39.

Change versus previous month

Short interest in Rallybio has recently decreased by 16.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rallybio does not currently pay a dividend.

Dividend Growth

Rallybio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.26

News Sentiment

Rallybio has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Rallybio this week, compared to 1 article on an average week.

Search Interest

1 people have searched for RLYB on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rallybio insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.30% of the stock of Rallybio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 10/27/2026
• Last Earnings: 10/27/2026
• Record date for 11/13 Dividend: 11/05/2026
• Next Earnings (Estimated): 11/05/2026
• Dividend Payable: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RLYB
• CIK: 1739410
• Web: www.rallybio.com
• Phone: (203) 859-3820
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 4,766,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A